Arrowhead Pharmaceuticals Inc. (HDP1)
Summary
HDP1 Chart
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher
Arrowhead Pharmaceuticals is positioned to challenge Ionis in severe hypertriglyceridemia (sHTG) with plozasiran, leveraging a faster launch via a $215M priority review voucher. ARWR's SHASTA-3 and SHASTA-4 Phase III data show plozasiran achieves 79–81% median triglyceride reductions and favorable safety, with quarterly dosing and no liver fat or thrombocytopenia signals. Current financials reflect partner-driven revenue and a strategic buildout for sHTG; liquidity of ~$1.35B post-voucher supports operations into early 2028, but further funding may be needed as SG&A rises.
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals NASDAQ: ARWR is expanding its commercial and clinical footprint around RNA interference therapies, with its recently launched triglyceride-lowering treatment REDEMPLO and several pipeline programs targeting cardiometabolic disease, obesity and central nervous system disorders.
Arrowhead Pharmaceuticals Inc. (HDP1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Arrowhead Pharmaceuticals Inc. ever had a stock split?
Arrowhead Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher R. Anzalone CEO | XMUN Exchange | US04280A1007 ISIN |
| US Country | 711 Employees | - Last Dividend | 17 Nov 2011 Last Split | 16 Jun 1993 IPO Date |
Overview
Arrowhead Pharmaceuticals, Inc. is a pioneering company focused on the development of innovative medicines for the treatment of intractable diseases. With a comprehensive pipeline of products undergoing various stages of clinical trials, the company is at the forefront of addressing challenging health conditions that impact populations in the United States. Arrowhead is dedicated to finding novel therapeutic solutions for patients with a range of diseases, leveraging cutting-edge research and strategic collaborations. Established in 2003 and based in Pasadena, California, the organization has formed key partnerships with industry leaders to advance its mission of bringing groundbreaking treatments to market.
Products and Services
Arrowhead Pharmaceuticals, Inc.'s robust pipeline encompasses a variety of products, each targeting specific intractable diseases through different stages of clinical development:
- Plozasiran - Currently in Phase 2b and one Phase 3 clinical trial, Plozasiran aims to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome, offering potential relief for patients with these lipid disorders.
- Zodasiran - In Phase 2b clinical trials, Zodasiran is being evaluated for its capability to treat dyslipidemia and hypertriglyceridemia, further highlighting Arrowhead’s commitment to addressing cardiovascular diseases.
- ARO-PNPLA3 - This candidate is in a Phase 1 clinical trial targeting non-alcoholic steatohepatitis (NASH), a liver condition that currently lacks sufficient therapeutic options.
- ARO-RAGE - Undergoing Phase 1/2a clinical trials, ARO-RAGE is developed for treating inflammatory pulmonary conditions, indicating Arrowhead’s foray into respiratory diseases.
- ARO-MUC5AC - This product is in Phase 1/2a clinical trials for the treatment of muco-obstructive pulmonary diseases, aiming to address unmet needs in pulmonary care.
- ARO-MMP7 - In Phase 1/2a clinical trials, ARO-MMP7 is targeted for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease.
- ARO-DUX4 - For patients with facioscapulohumeral muscular dystrophy, ARO-DUX4 represents a hopeful treatment currently in development.
- ARO-SOD1 - Arrowhead is exploring the potential treatment of amyotrophic lateral sclerosis (ALS) with ARO-SOD1.
- ARO-C3 - In Phase 1/2a clinical trial, ARO-C3 targets various complement mediated or associated renal diseases, extending its efforts to renal health.
- JNJ-3989 - Partnered with Janssen Pharmaceuticals, Inc., this product in Phase 2 clinical trial aims to treat chronic hepatitis B virus infection.
- Olpasiran - This candidate is in a crucial Phase 3 clinical trial to reduce the production of apolipoprotein A, a factor in cardiovascular disease.
- GSK-4532990 - In collaboration with GlaxoSmithKline, this Phase 2 clinical trial candidate seeks to address liver diseases, showing the breadth of Arrowhead's therapeutic aims.
- HZN-457 - Developed in partnership with Horizon Therapeutics Ireland DAC, HZN-457 is currently in phase 1 clinical trial targeting uncontrolled gout.
- Fazirsiran - In a Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency, Fazirsiran signifies Arrowhead's commitment to liver health.
Moreover, Arrowhead Pharmaceuticals has entered into strategic license and research collaboration agreements with notable entities including Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Horizon Therapeutics Ireland DAC, Amgen Inc., and GlaxoSmithKline Intellectual Property (No. 3) Limited, underscoring its collaborative and innovative approach to drug development.
Contact Information
